Kan Li1, Wenyaw Chan1, Rachelle S Doody2, Joseph Quinn3, Sheng Luo1. 1. Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, TX, USA. 2. F. Hoffman-La Roche, Basel, Switzerland. 3. Department of Neurology, Oregon Health and Science University and Portland VA Medical Center, Portland, OR, USA.
Abstract
BACKGROUND: Identifying predictors of conversion to Alzheimer's disease (AD) is critically important for AD prevention and targeted treatment. OBJECTIVE: To compare various clinical and biomarker trajectories for tracking progression and predicting conversion from amnestic mild cognitive impairment to probable AD. METHODS: Participants were from the ADNI-1 study. We assessed the ability of 33 longitudinal biomarkers to predict time to AD conversion, accounting for demographic and genetic factors. We used joint modelling of longitudinal and survival data to examine the association between changes of measures and disease progression. We also employed time-dependent receiver operating characteristic method to assess the discriminating capability of the measures. RESULTS: 23 of 33 longitudinal clinical and imaging measures are significant predictors of AD conversion beyond demographic and genetic factors. The strong phenotypic and biological predictors are in the cognitive domain (ADAS-Cog; RAVLT), functional domain (FAQ), and neuroimaging domain (middle temporal gyrus and hippocampal volume). The strongest predictor is ADAS-Cog 13 with an increase of one SD in ADAS-Cog 13 increased the risk of AD conversion by 2.92 times. CONCLUSION: Prediction of AD conversion can be improved by incorporating longitudinal change information, in addition to baseline characteristics. Cognitive measures are consistently significant and generally stronger predictors than imaging measures.
BACKGROUND: Identifying predictors of conversion to Alzheimer's disease (AD) is critically important for AD prevention and targeted treatment. OBJECTIVE: To compare various clinical and biomarker trajectories for tracking progression and predicting conversion from amnestic mild cognitive impairment to probable AD. METHODS:Participants were from the ADNI-1 study. We assessed the ability of 33 longitudinal biomarkers to predict time to AD conversion, accounting for demographic and genetic factors. We used joint modelling of longitudinal and survival data to examine the association between changes of measures and disease progression. We also employed time-dependent receiver operating characteristic method to assess the discriminating capability of the measures. RESULTS: 23 of 33 longitudinal clinical and imaging measures are significant predictors of AD conversion beyond demographic and genetic factors. The strong phenotypic and biological predictors are in the cognitive domain (ADAS-Cog; RAVLT), functional domain (FAQ), and neuroimaging domain (middle temporal gyrus and hippocampal volume). The strongest predictor is ADAS-Cog 13 with an increase of one SD in ADAS-Cog 13 increased the risk of AD conversion by 2.92 times. CONCLUSION: Prediction of AD conversion can be improved by incorporating longitudinal change information, in addition to baseline characteristics. Cognitive measures are consistently significant and generally stronger predictors than imaging measures.
Authors: C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen Journal: Neurology Date: 1999-04-22 Impact factor: 9.910
Authors: Robert A Lenz; Yili L Pritchett; Scott M Berry; Daniel A Llano; Shu Han; Donald A Berry; Carl H Sadowsky; Walid M Abi-Saab; Mario D Saltarelli Journal: Alzheimer Dis Assoc Disord Date: 2015 Jul-Sep Impact factor: 2.703
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Shannon L Risacher; Andrew J Saykin; John D West; Li Shen; Hiram A Firpi; Brenna C McDonald Journal: Curr Alzheimer Res Date: 2009-08 Impact factor: 3.498
Authors: Christine Fennema-Notestine; Donald J Hagler; Linda K McEvoy; Adam S Fleisher; Elaine H Wu; David S Karow; Anders M Dale Journal: Hum Brain Mapp Date: 2009-10 Impact factor: 5.038
Authors: A S Fleisher; S Sun; C Taylor; C P Ward; A C Gamst; R C Petersen; C R Jack; P S Aisen; L J Thal Journal: Neurology Date: 2008-01-15 Impact factor: 9.910
Authors: María Eugenia López; Agustín Turrero; Pablo Cuesta; Inmaculada Concepción Rodríguez-Rojo; Ana Barabash; Alberto Marcos; Fernando Maestú; Alberto Fernández Journal: Geroscience Date: 2020-09-04 Impact factor: 7.713
Authors: Daniele Altomare; Clarissa Ferrari; Anna Caroli; Samantha Galluzzi; Annapaola Prestia; Wiesje M van der Flier; Rik Ossenkoppele; Bart Van Berckel; Frederik Barkhof; Charlotte E Teunissen; Anders Wall; Stephen F Carter; Michael Schöll; I L Han Choo; Timo Grimmer; Alberto Redolfi; Agneta Nordberg; Philip Scheltens; Alexander Drzezga; Giovanni B Frisoni Journal: J Neurol Date: 2019-07-02 Impact factor: 4.849